Shopping Cart
- Remove All
- Your shopping cart is currently empty
GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype-selective Nav1.7 inhibitor [Ki: 0.79 nM, Kd: 0.38 nM for hNav1.7] for the treatment of chronic pain.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $3,170 | 10-14 weeks | |
50 mg | $4,180 | 10-14 weeks | |
100 mg | $5,800 | 10-14 weeks |
Description | GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype-selective Nav1.7 inhibitor [Ki: 0.79 nM, Kd: 0.38 nM for hNav1.7] for the treatment of chronic pain. |
Targets&IC50 | Nav1.6 (human):29 nM (ki), Nav1.2 (human):12 nM (ki), Nav1.7 (human): kd:0.38 nM , Nav1.7 (human):ki:0.79 nM |
In vitro | Site-directed mutagenesis is essential for determining the isoform selectivity profile of GNE-616. |
In vivo | GNE-616 demonstrates significant activity in a Nav1.7-dependent inherited erythromelalgia (IEM) PK/PD model. |
Molecular Weight | 537.53 |
Formula | C24H23F4N5O3S |
Cas No. | 2349371-81-7 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.